"We also generated a novel polygenic risk score strongly associated
with the risk of future dementia or progression from mild cognitive impairment to dementia."https://www.medrxiv.org/content/10.1101 ... 2.full.pdf
I believe them.
This could start to move the ball forward for clinical trials.
We could see precise genetic selection of those who would be most likely to benefit in a clinical trial.
AD clinical trials used to have ~40% of AD patients who did not have AD.
Then they introduced amyloid positive inclusion requirements; yet even then a significant percentage of patients
would not progress during a 78 week trial. Finding the right patients could make a very large difference.